Published in Nat Rev Gastroenterol Hepatol on August 16, 2011
The interplay between the intestinal microbiota and the brain. Nat Rev Microbiol (2012) 2.83
Transient inability to manage proteobacteria promotes chronic gut inflammation in TLR5-deficient mice. Cell Host Microbe (2012) 2.48
AIEC pathobiont instigates chronic colitis in susceptible hosts by altering microbiota composition. Gut (2013) 2.08
Probiotic bacteria reduce salmonella typhimurium intestinal colonization by competing for iron. Cell Host Microbe (2013) 2.06
PathogenFinder--distinguishing friend from foe using bacterial whole genome sequence data. PLoS One (2013) 1.97
Complex interactions among diet, gastrointestinal transit, and gut microbiota in humanized mice. Gastroenterology (2013) 1.86
Absence of the intestinal microbiota exacerbates hepatobiliary disease in a murine model of primary sclerosing cholangitis. Hepatology (2015) 1.65
Microbial contact during pregnancy, intestinal colonization and human disease. Nat Rev Gastroenterol Hepatol (2012) 1.62
The gut microbiota and obesity: from correlation to causality. Nat Rev Microbiol (2013) 1.59
Intestinal permeability--a new target for disease prevention and therapy. BMC Gastroenterol (2014) 1.52
The Typhoid Toxin Promotes Host Survival and the Establishment of a Persistent Asymptomatic Infection. PLoS Pathog (2016) 1.43
Inflammatory bowel disease as a model for translating the microbiome. Immunity (2014) 1.39
Integrative analysis of the microbiome and metabolome of the human intestinal mucosal surface reveals exquisite inter-relationships. Microbiome (2013) 1.32
Resistant starch: promise for improving human health. Adv Nutr (2013) 1.24
The impact of probiotics and prebiotics on the immune system. Nat Rev Immunol (2012) 1.19
Changes in the rumen epimural bacterial diversity of beef cattle as affected by diet and induced ruminal acidosis. Appl Environ Microbiol (2013) 1.16
Neuropeptide Y, peptide YY and pancreatic polypeptide in the gut-brain axis. Neuropeptides (2012) 1.16
Pyrosequencing of 16S rRNA genes in fecal samples reveals high diversity of hindgut microflora in horses and potential links to chronic laminitis. BMC Vet Res (2012) 1.11
Trichuris muris: a model of gastrointestinal parasite infection. Semin Immunopathol (2012) 1.04
Chronic exposure to the cytolethal distending toxins of Gram-negative bacteria promotes genomic instability and altered DNA damage response. Cell Microbiol (2012) 1.00
Duodenal-mucosal bacteria associated with celiac disease in children. Appl Environ Microbiol (2013) 0.98
Alteration of the fecal microbiota and serum metabolite profiles in dogs with idiopathic inflammatory bowel disease. Gut Microbes (2015) 0.98
Faecalibacterium prausnitzii prevents physiological damages in a chronic low-grade inflammation murine model. BMC Microbiol (2015) 0.98
Role of the microbiota and antibiotics in primary sclerosing cholangitis. Biomed Res Int (2013) 0.97
From microbe to man: the role of microbial short chain fatty acid metabolites in host cell biology. Am J Physiol Cell Physiol (2014) 0.96
Microbial translocation and microbiome dysbiosis in HIV-associated immune activation. Curr Opin HIV AIDS (2016) 0.94
A novel SCFA receptor, the microbiota, and blood pressure regulation. Gut Microbes (2013) 0.93
The role of the gut microbiota in NAFLD. Nat Rev Gastroenterol Hepatol (2016) 0.93
Epidemiology, demographic characteristics and prognostic predictors of ulcerative colitis. World J Gastroenterol (2014) 0.93
Current status and future promise of the human microbiome. Pediatr Gastroenterol Hepatol Nutr (2013) 0.93
Ecotoxicology inside the gut: impact of heavy metals on the mouse microbiome. BMC Pharmacol Toxicol (2013) 0.89
Dysbiosis of fungal microbiota in the intestinal mucosa of patients with colorectal adenomas. Sci Rep (2015) 0.87
Dietary Factors: Major Regulators of the Gut's Microbiota. Gut Liver (2012) 0.86
Gut microbes and host physiology: what happens when you host billions of guests? Front Endocrinol (Lausanne) (2014) 0.86
Human pharyngeal microbiome may play a protective role in respiratory tract infections. Genomics Proteomics Bioinformatics (2014) 0.84
Lactobacillus rhamnosus CNCM I-3690 and the commensal bacterium Faecalibacterium prausnitzii A2-165 exhibit similar protective effects to induced barrier hyper-permeability in mice. Gut Microbes (2015) 0.83
Fecal microbes, short chain fatty acids, and colorectal cancer across racial/ethnic groups. World J Gastroenterol (2015) 0.83
Neural networks in intestinal immunoregulation. Organogenesis (2013) 0.82
Visceral pain and gastrointestinal microbiome. J Neurogastroenterol Motil (2015) 0.81
On the Origins and Control of Community Types in the Human Microbiome. PLoS Comput Biol (2016) 0.80
Brain injury induces specific changes in the caecal microbiota of mice via altered autonomic activity and mucoprotein production. Brain Behav Immun (2016) 0.80
Chemoprevention in gastrointestinal physiology and disease. Natural products and microbiome. Am J Physiol Gastrointest Liver Physiol (2014) 0.80
Murine norovirus infection does not cause major disruptions in the murine intestinal microbiota. Microbiome (2013) 0.80
Direct Detection and Quantification of Bacterial Genes Associated with Inflammation in DNA Isolated from Stool. Adv Microbiol (2014) 0.79
Gut Microbiota and Lifestyle Interventions in NAFLD. Int J Mol Sci (2016) 0.79
Inflammation in irritable bowel syndrome: Myth or new treatment target? World J Gastroenterol (2016) 0.79
Plasticity of the brush border - the yin and yang of intestinal homeostasis. Nat Rev Gastroenterol Hepatol (2016) 0.79
Germ-free mice as a model to study effect of gut microbiota on host physiology. Neurogastroenterol Motil (2014) 0.78
Advances in IBS 2016: A Review of Current and Emerging Data. Gastroenterol Hepatol (N Y) (2016) 0.78
Effect of dietary monosaccharides on Pseudomonas aeruginosa virulence. Surg Infect (Larchmt) (2013) 0.77
Effects of a high fat diet on intestinal microbiota and gastrointestinal diseases. World J Gastroenterol (2016) 0.77
Mucosa-associated microbiota signature in colorectal cancer. Eur J Clin Microbiol Infect Dis (2017) 0.77
The Burden of Enteropathy and "Subclinical" Infections. Pediatr Clin North Am (2017) 0.76
Prospective Clinical Trial of Rifaximin Therapy for Patients With Primary Sclerosing Cholangitis. Am J Ther (2014) 0.76
Bioengineering: a bacteriocin perspective. Bioengineered (2012) 0.76
Human colon-derived soluble factors modulate gut microbiota composition. Front Oncol (2015) 0.76
The tuning of the gut nervous system by commensal microbiota. Gastroenterology (2013) 0.76
Systems biology of host-fungus interactions: turning complexity into simplicity. Curr Opin Microbiol (2012) 0.76
Circadian Rhythm Shapes the Gut Microbiota Affecting Host Radiosensitivity. Int J Mol Sci (2016) 0.76
CXCR4/IgG-expressing plasma cells are associated with human gastrointestinal tissue inflammation. J Allergy Clin Immunol (2013) 0.76
Probiotic-derived ferrichrome inhibits colon cancer progression via JNK-mediated apoptosis. Nat Commun (2016) 0.75
Gut microbiota in renal physiology: focus on short-chain fatty acids and their receptors. Kidney Int (2016) 0.75
Obesity and microbiota: an example of an intricate relationship. Genes Nutr (2017) 0.75
Associations of Bowel Movement Frequency with Risk of Cardiovascular Disease and Mortality among US Women. Sci Rep (2016) 0.75
ILSI Brazil International Workshop on Functional Foods: a narrative review of the scientific evidence in the area of carbohydrates, microbiome, and health. Food Nutr Res (2013) 0.75
Immune modulating capability of two exopolysaccharide-producing Bifidobacterium strains in a Wistar rat model. Biomed Res Int (2014) 0.75
Modeling environmental risk factors of autism in mice induces IBD-related gut microbial dysbiosis and hyperserotonemia. Mol Brain (2017) 0.75
Phasic study of intestinal homeostasis disruption in experimental intestinal obstruction. World J Gastroenterol (2014) 0.75
Aflatoxin B1 Induced Compositional Changes in Gut Microbial Communities of Male F344 Rats. Toxicol Sci (2015) 0.75
Bile microbiota in primary sclerosing cholangitis: Impact on disease progression and development of biliary dysplasia. PLoS One (2017) 0.75
Metagenomic analysis of the human distal gut microbiome. Science (2006) 29.76
Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell (2004) 29.32
Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci U S A (2007) 20.60
The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. PLoS Biol (2008) 16.57
Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach. Gut (2005) 10.95
Temperature gradient gel electrophoresis analysis of 16S rRNA from human fecal samples reveals stable and host-specific communities of active bacteria. Appl Environ Microbiol (1998) 10.67
Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med (2011) 10.03
Microbial influences in inflammatory bowel diseases. Gastroenterology (2008) 9.20
Mucosal flora in inflammatory bowel disease. Gastroenterology (2002) 8.42
AGA technical review on irritable bowel syndrome. Gastroenterology (2002) 6.76
High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease. Gastroenterology (2004) 5.94
Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol (2000) 5.72
Spatial organization and composition of the mucosal flora in patients with inflammatory bowel disease. J Clin Microbiol (2005) 5.62
Dominant and diet-responsive groups of bacteria within the human colonic microbiota. ISME J (2010) 5.43
Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease. Gut (2004) 5.32
Alterations of the dominant faecal bacterial groups in patients with Crohn's disease of the colon. Gut (2003) 5.19
The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology (2007) 5.04
Effect of faecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum. Lancet (1991) 5.02
Enhanced Escherichia coli adherence and invasion in Crohn's disease and colon cancer. Gastroenterology (2004) 4.89
Changes in the composition of the human fecal microbiome after bacteriotherapy for recurrent Clostridium difficile-associated diarrhea. J Clin Gastroenterol (2010) 4.52
Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease. Gastroenterology (2004) 4.42
Lymphoid tissue genesis induced by commensals through NOD1 regulates intestinal homeostasis. Nature (2008) 4.42
Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome. Neurogastroenterol Motil (2009) 4.28
Aberrant mucin assembly in mice causes endoplasmic reticulum stress and spontaneous inflammation resembling ulcerative colitis. PLoS Med (2008) 4.24
Deletion of TLR5 results in spontaneous colitis in mice. J Clin Invest (2007) 4.18
Increased intestinal permeability in patients with Crohn's disease and their relatives. A possible etiologic factor. Ann Intern Med (1986) 4.18
The immune geography of IgA induction and function. Mucosal Immunol (2008) 4.06
Lactulose breath testing does not discriminate patients with irritable bowel syndrome from healthy controls. Am J Gastroenterol (2008) 3.95
The interdigestive motor complex of normal subjects and patients with bacterial overgrowth of the small intestine. J Clin Invest (1977) 3.89
Long-term impacts of antibiotic exposure on the human intestinal microbiota. Microbiology (2010) 3.68
The Firmicutes/Bacteroidetes ratio of the human microbiota changes with age. BMC Microbiol (2009) 3.58
Postinfectious irritable bowel syndrome. Gastroenterology (2009) 3.17
Maintenance of colonic homeostasis by distinctive apical TLR9 signalling in intestinal epithelial cells. Nat Cell Biol (2006) 3.16
Interactions between the host innate immune system and microbes in inflammatory bowel disease. Gastroenterology (2011) 2.90
Agent transmissible from Crohn's disease tissue. Lancet (1970) 2.89
Twin studies reveal specific imbalances in the mucosa-associated microbiota of patients with ileal Crohn's disease. Inflamm Bowel Dis (2009) 2.85
Microbial dysbiosis in colorectal cancer (CRC) patients. PLoS One (2011) 2.84
Small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Gut (2006) 2.82
Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome. JAMA (2004) 2.67
Gut microbiome-host interactions in health and disease. Genome Med (2011) 2.48
The commensal microbiota and enteropathogens in the pathogenesis of inflammatory bowel diseases. Gastroenterology (2011) 2.41
Diarrhoea-predominant irritable bowel syndrome distinguishable by 16S rRNA gene phylotype quantification. World J Gastroenterol (2009) 2.39
Increased intestinal permeability to macromolecules and endotoxemia in patients with chronic alcohol abuse in different stages of alcohol-induced liver disease. J Hepatol (2000) 2.36
The diagnosis of small bowel bacterial overgrowth. Reliability of jejunal culture and inadequacy of breath hydrogen testing. Gastroenterology (1990) 2.32
The leaky gut of alcoholism: possible route of entry for toxic compounds. Lancet (1984) 2.30
Probiotics and the gut microbiota in intestinal health and disease. Nat Rev Gastroenterol Hepatol (2010) 2.22
Association between intraepithelial Escherichia coli and colorectal cancer. Gastroenterology (1998) 2.15
Crohn disease--associated adherent-invasive E. coli bacteria target mouse and human Peyer's patches via long polar fimbriae. J Clin Invest (2011) 2.10
Lower frequency of MMC is found in IBS subjects with abnormal lactulose breath test, suggesting bacterial overgrowth. Dig Dis Sci (2002) 1.90
Sporadic colorectal cancer--role of the commensal microbiota. FEMS Microbiol Lett (2005) 1.82
Antibodies to flagellin indicate reactivity to bacterial antigens in IBS patients. Neurogastroenterol Motil (2008) 1.80
The role of the intestinal microflora in experimental colitis. Am J Clin Nutr (1977) 1.80
The bacteriology of biopsies differs between newly diagnosed, untreated, Crohn's disease and ulcerative colitis patients. J Med Microbiol (2006) 1.79
Rifaximin modulates the colonic microbiota of patients with Crohn's disease: an in vitro approach using a continuous culture colonic model system. J Antimicrob Chemother (2010) 1.79
Success of self-administered home fecal transplantation for chronic Clostridium difficile infection. Clin Gastroenterol Hepatol (2010) 1.77
Microbial community analysis reveals high level phylogenetic alterations in the overall gastrointestinal microbiota of diarrhoea-predominant irritable bowel syndrome sufferers. BMC Gastroenterol (2009) 1.76
Highlighting new phylogenetic specificities of Crohn's disease microbiota. Inflamm Bowel Dis (2010) 1.70
The response of the lymphatic tissue to the microbial flora. Studies on germfree mice. Am J Pathol (1963) 1.70
Infections and cancer: established associations and new hypotheses. Crit Rev Oncol Hematol (2008) 1.70
The reduction of azo dyes by the intestinal microflora. Crit Rev Microbiol (1992) 1.69
Highly resistant Salmonella Newport-MDRAmpC transmitted through the domestic US food supply: a FoodNet case-control study of sporadic Salmonella Newport infections, 2002-2003. J Infect Dis (2006) 1.62
Durable alteration of the colonic microbiota by the administration of donor fecal flora. J Clin Gastroenterol (2010) 1.62
Mechanisms of probiotic actions - A review. Int J Med Microbiol (2009) 1.61
Variability of motility of the ileum and jejunum in healthy humans. Gastroenterology (1982) 1.57
Oral bile acids reduce bacterial overgrowth, bacterial translocation, and endotoxemia in cirrhotic rats. Hepatology (2003) 1.51
Gastrointestinal microbiota in irritable bowel syndrome: present state and perspectives. Microbiology (2010) 1.50
Sporadic Campylobacter jejuni infections in Hawaii: associations with prior antibiotic use and commercially prepared chicken. J Infect Dis (2001) 1.49
New pathophysiological mechanisms in irritable bowel syndrome. Aliment Pharmacol Ther (2004) 1.45
Determinants of the human infant intestinal microbiota after the introduction of first complementary foods in infant samples from five European centres. Microbiology (2011) 1.44
The enhancing effect of the microbial flora on macrophage function and the immune response. A study in germfree mice. J Exp Med (1966) 1.33
Role of small intestinal bacterial overgrowth and delayed gastrointestinal transit time in cirrhotic patients with minimal hepatic encephalopathy. J Hepatol (2010) 1.31
A systematic review of diagnostic tests for small intestinal bacterial overgrowth. Dig Dis Sci (2008) 1.28
The immune-enhancing effects of dietary fibres and prebiotics. Br J Nutr (2002) 1.27
Methane and the gastrointestinal tract. Dig Dis Sci (2009) 1.24
Immunopathogenesis of inflammatory bowel disease. Self Nonself (2011) 1.24
Comparison of the fecal microbiota profiles between ulcerative colitis and Crohn's disease using terminal restriction fragment length polymorphism analysis. J Gastroenterol (2011) 1.23
Flag in the crossroads: flagellin modulates innate and adaptive immunity. Curr Opin Gastroenterol (2006) 1.22
Enteric microbial flora, bacterial overgrowth, and short-bowel syndrome. Clin Gastroenterol Hepatol (2006) 1.22
Small intestinal bacterial overgrowth in human cirrhosis is associated with systemic endotoxemia. Am J Gastroenterol (2002) 1.22
Evidence for polymicrobic flora translocating in peripheral blood of HIV-infected patients with poor immune response to antiretroviral therapy. PLoS One (2011) 1.21
Intestinal permeability in liver cirrhosis: relationship with severe septic complications. Eur J Gastroenterol Hepatol (1999) 1.21
Pretreatment of epithelial cells with rifaximin alters bacterial attachment and internalization profiles. Antimicrob Agents Chemother (2009) 1.20
Abnormal breath testing in IBS: a meta-analysis. Dig Dis Sci (2010) 1.20
Hydrogen glucose breath test to detect small intestinal bacterial overgrowth: a prevalence case-control study in irritable bowel syndrome. Aliment Pharmacol Ther (2005) 1.19
Small-intestinal bacterial overgrowth in cirrhosis is related to the severity of liver disease. Aliment Pharmacol Ther (2009) 1.19
Probiotics and prebiotics in inflammatory bowel disease: microflora 'on the scope'. Br J Clin Pharmacol (2008) 1.18
Failure of ciprofloxacin to eradicate convalescent fecal excretion after acute salmonellosis: experience during an outbreak in health care workers. Ann Intern Med (1991) 1.16
Altered peripheral toll-like receptor responses in the irritable bowel syndrome. Aliment Pharmacol Ther (2011) 1.10
Increased uptake of non-pathogenic E. coli via the follicle-associated epithelium in longstanding ileal Crohn's disease. J Pathol (2008) 1.05
Small bowel bacterial overgrowth in patients with alcoholic cirrhosis. Dig Dis Sci (1995) 1.05
Review article: anti-inflammatory mechanisms of action of Saccharomyces boulardii. Aliment Pharmacol Ther (2008) 1.04
Role of NF-kappaB activation in intestinal immune homeostasis. Int J Med Microbiol (2009) 1.02
Is the abundance of Faecalibacterium prausnitzii relevant to Crohn's disease? FEMS Microbiol Lett (2010) 1.02
Escherichia coli isolates causing bacteremia via gut translocation and urinary tract infection in young infants exhibit different virulence genotypes. J Infect Dis (2011) 1.01
Altered intestinal microbiota in irritable bowel syndrome. Neurogastroenterol Motil (2010) 1.00
Small intestinal motility disturbances and bacterial overgrowth in patients with liver cirrhosis and portal hypertension. Am J Gastroenterol (2003) 1.00
Breath test for differential diagnosis between small intestinal bacterial overgrowth and irritable bowel disease: an observation on non-absorbable antibiotics. World J Gastroenterol (2007) 0.99
Human intestinal microbiota: cross-talk with the host and its potential role in colorectal cancer. Crit Rev Microbiol (2010) 0.99
Small bowel bacterial overgrowth in patients with alcoholic cirrhosis. Dig Dis Sci (1996) 0.98
A phylogenetic group of Escherichia coli associated with active left-sided inflammatory bowel disease. BMC Microbiol (2009) 0.98
Problem pathogens: extra-intestinal complications of Salmonella enterica serotype Typhi infection. Lancet Infect Dis (2005) 2.67
The practice of travel medicine: guidelines by the Infectious Diseases Society of America. Clin Infect Dis (2006) 2.60
Post-diarrhea chronic intestinal symptoms and irritable bowel syndrome in North American travelers to Mexico. Am J Gastroenterol (2004) 1.98
Rifaximin--a novel antimicrobial for enteric infections. J Infect (2005) 1.79
Therapy of travelers' diarrhea with rifaximin on various continents. Am J Gastroenterol (2003) 1.77
Noroviruses: The leading cause of gastroenteritis worldwide. Discov Med (2010) 1.73
Antimotility agents for the treatment of Clostridium difficile diarrhea and colitis. Clin Infect Dis (2009) 1.70
Prevalence of enteric pathogens among international travelers with diarrhea acquired in Kenya (Mombasa), India (Goa), or Jamaica (Montego Bay). J Infect Dis (2002) 1.64
Enteric pathogens in Mexican sauces of popular restaurants in Guadalajara, Mexico, and Houston, Texas. Ann Intern Med (2002) 1.61
A review of an emerging enteric pathogen: enteroaggregative Escherichia coli. J Med Microbiol (2006) 1.54
Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases. Curr Opin Gastroenterol (2010) 1.50
Global etiology of travelers' diarrhea: systematic review from 1973 to the present. Am J Trop Med Hyg (2009) 1.49
Persistent abdominal symptoms in US adults after short-term stay in Mexico. J Travel Med (2014) 1.47
The role of diet in the treatment of travelers' diarrhea: a pilot study. Clin Infect Dis (2004) 1.45
Seroepidemiology of norovirus-associated travelers' diarrhea. J Travel Med (2014) 1.43
Association of interleukin-8 polymorphism and immunoglobulin G anti-toxin A in patients with Clostridium difficile-associated diarrhea. Clin Gastroenterol Hepatol (2007) 1.41
The controversial and short-lived early use of rehydration therapy for cholera. Clin Infect Dis (2008) 1.38
Enteroaggregative Escherichia coli is a cause of acute diarrheal illness: a meta-analysis. Clin Infect Dis (2006) 1.38
Clostridium difficile infection: update on emerging antibiotic treatment options and antibiotic resistance. Expert Rev Anti Infect Ther (2010) 1.35
Genetic susceptibility to enteroaggregative Escherichia coli diarrhea: polymorphism in the interleukin-8 promotor region. J Infect Dis (2003) 1.30
Markers of inflammation in bacterial diarrhea among travelers, with a focus on enteroaggregative Escherichia coli pathogenicity. J Infect Dis (2002) 1.25
Rifaximin: a novel nonabsorbed rifamycin for gastrointestinal disorders. Clin Infect Dis (2006) 1.21
Epidemiology of travelers' diarrhea: details of a global survey. J Travel Med (2004) 1.21
Association of diarrheagenic Escherichia coli Pathotypes with infection and diarrhea among Mexican children and association of atypical Enteropathogenic E. coli with acute diarrhea. J Clin Microbiol (2008) 1.21
Rate of occurrence and pathogenic effect of enteroaggregative Escherichia coli virulence factors in international travelers. J Clin Microbiol (2002) 1.19
A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection. J Antimicrob Chemother (2011) 1.18
Enteroaggregative Escherichia coli: an emerging enteric pathogen. Am J Gastroenterol (2004) 1.18
Natural history of enteroaggregative and enterotoxigenic Escherichia coli infection among US travelers to Guadalajara, Mexico. J Infect Dis (2002) 1.15
Asymptomatic norovirus infection in Mexican children. J Clin Microbiol (2006) 1.13
Real-time polymerase chain reaction detection of asymptomatic Clostridium difficile colonization and rising C. difficile-associated disease rates. Infect Control Hosp Epidemiol (2014) 1.12
Association of putative enteroaggregative Escherichia coli virulence genes and biofilm production in isolates from travelers to developing countries. J Clin Microbiol (2006) 1.09
A novel single-nucleotide polymorphism in the lactoferrin gene is associated with susceptibility to diarrhea in North American travelers to Mexico. Clin Infect Dis (2007) 1.09
Drug-resistant diarrheogenic Escherichia coli, Mexico. Emerg Infect Dis (2005) 1.08
A common polymorphism in the interleukin 8 gene promoter is associated with Clostridium difficile diarrhea. Am J Gastroenterol (2006) 1.06
Intestinal decontamination inhibits TLR4 dependent fibronectin-mediated cross-talk between stellate cells and endothelial cells in liver fibrosis in mice. J Hepatol (2011) 1.05
Virulence characteristics and the molecular epidemiology of enteroaggregative Escherichia coli isolates from travellers to developing countries. J Med Microbiol (2007) 1.03
Enterotoxigenic Escherichia coli as cause of diarrhea among Mexican adults and US travelers in Mexico. J Travel Med (2002) 1.03
Noroviruses as a cause of traveler's diarrhea among students from the United States visiting Mexico. J Clin Microbiol (2005) 1.03
Interleukin-8 response in an intestinal HCT-8 cell line infected with enteroaggregative and enterotoxigenic Escherichia coli. Clin Diagn Lab Immunol (2004) 1.02
Etiology and pharmacologic management of noninfectious diarrhea in HIV-infected individuals in the highly active antiretroviral therapy era. Clin Infect Dis (2012) 1.02
Rifamycin antibiotics for treatment of Clostridium difficile-associated diarrhea. Ann Pharmacother (2008) 0.99
Associations between mucosal innate and adaptive immune responses and resolution of diarrheal pathogen infections. Infect Immun (2009) 0.98
Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections. Expert Rev Anti Infect Ther (2005) 0.97
Bile acids improve the antimicrobial effect of rifaximin. Antimicrob Agents Chemother (2010) 0.97
Impact of vitamin A on selected gastrointestinal pathogen infections and associated diarrheal episodes among children in Mexico City, Mexico. J Infect Dis (2006) 0.97
The search for effective treatment of Clostridium difficile infection. N Engl J Med (2011) 0.95
Effect of vitamin A and zinc supplementation on gastrointestinal parasitic infections among Mexican children. Pediatrics (2007) 0.94
The effect of vitamin A supplementation on the intestinal immune response in Mexican children is modified by pathogen infections and diarrhea. J Nutr (2006) 0.93
In vitro antimicrobial susceptibility of bacterial enteropathogens isolated from international travelers to Mexico, Guatemala, and India from 2006 to 2008. Antimicrob Agents Chemother (2010) 0.93
Influence of host interleukin-10 polymorphisms on development of traveler's diarrhea due to heat-labile enterotoxin-producing Escherichia coli in travelers from the United States who are visiting Mexico. Clin Vaccine Immunol (2008) 0.93
The patient presenting with acute dysentery--a systematic review. J Infect (2012) 0.92
Enterotoxigenic Escherichia coli heat-labile toxin seroconversion in US travelers to Mexico. J Travel Med (2008) 0.92
Noroviruses as a cause of diarrhea in travelers to Guatemala, India, and Mexico. J Clin Microbiol (2010) 0.92
Toxin synthesis by Clostridium difficile is regulated through quorum signaling. MBio (2015) 0.91
Advances in defining etiology and new therapeutic approaches in acute diarrhea. J Infect (2007) 0.91
Current and future developments in travelers' diarrhea therapy. Expert Rev Anti Infect Ther (2006) 0.91
Patterns of illness in travelers visiting Mexico and Central America: the GeoSentinel experience. Clin Infect Dis (2011) 0.90
Fecal cytokines and markers of intestinal inflammation in international travelers with diarrhea due to Noroviruses. J Med Virol (2006) 0.90
Enteroaggregative Escherichia coli diarrhea in travelers: response to rifaximin therapy. Clin Gastroenterol Hepatol (2004) 0.89
Loperamide plus azithromycin more effectively treats travelers' diarrhea in Mexico than azithromycin alone. J Travel Med (2007) 0.89
Noroviruses as a potential cause of protracted and lethal disease in immunocompromised patients. Clin Infect Dis (2009) 0.88
Enterotoxigenic Escherichia coli and diffusely adherent E. coli as likely causes of a proportion of pathogen-negative travelers' diarrhea--a PCR-based study. J Travel Med (2008) 0.85
Randomized, double-blind, placebo-controlled clinical trial of loperamide plus simethicone versus loperamide alone and simethicone alone in the treatment of acute diarrhea with gas-related abdominal discomfort. Curr Med Res Opin (2007) 0.85
Single nucleotide polymorphisms in the promoter of the gene encoding the lipopolysaccharide receptor CD14 are associated with bacterial diarrhea in US and Canadian travelers to Mexico. Clin Infect Dis (2011) 0.85
Seroprevalence of the enteroaggregative Escherichia coli virulence factor dispersin among USA travellers to Cuernavaca, Mexico: a pilot study. J Med Microbiol (2008) 0.85
A double blind, randomized, placebo-controlled study of SP-303 (Provir) in the symptomatic treatment of acute diarrhea among travelers to Jamaica and Mexico. Am J Gastroenterol (2002) 0.84
Improvement in detection of enterotoxigenic Escherichia coli in patients with travelers' diarrhea by increasing the number of E. coli colonies tested. Am J Trop Med Hyg (2009) 0.84
Seasonality of diarrheagenic Escherichia coli pathotypes in the US students acquiring diarrhea in Mexico. J Travel Med (2011) 0.84
Characterization of the human gut microbiome during travelers' diarrhea. Gut Microbes (2015) 0.84
A hospital-based study of the clinical characteristics of Clostridium difficile infection in children. Pediatr Infect Dis J (2014) 0.83
Azithromycin found to be comparable to levofloxacin for the treatment of US travelers with acute diarrhea acquired in Mexico. Clin Infect Dis (2003) 0.82
Supplementation with vitamin A reduces watery diarrhoea and respiratory infections in Mexican children. Br J Nutr (2007) 0.82
Prevention of travelers' diarrhea with rifaximin in US travelers to Mexico. J Travel Med (2010) 0.82
Detection of enteroaggregative Escherichia coli with formalin-preserved HEp-2 cells. J Clin Microbiol (2002) 0.81
Vitamin A modifies the intestinal chemokine and cytokine responses to norovirus infection in Mexican children. J Nutr (2011) 0.81
Rifaximin: a nonsystemic rifamycin antibiotic for gastrointestinal infections. Expert Rev Anti Infect Ther (2010) 0.81
Colonic immunopathogenesis of Clostridium difficile infections. Clin Vaccine Immunol (2014) 0.81
Epidemiology of cryptosporidiosis in North American travelers to Mexico. Am J Trop Med Hyg (2008) 0.81
Motility abnormalities in irritable bowel syndrome. Digestion (2014) 0.80
Azithromycin for the self-treatment of traveler's diarrhea. Clin Infect Dis (2006) 0.80
Enteroinvasive Escherichia coli severe dysentery complicated by rotavirus gastroenteritis. J Infect (2006) 0.79
Efficacy of a travelers' diarrhea vaccine system in travelers to India. J Travel Med (2013) 0.79
Bile salt inhibition of host cell damage by Clostridium difficile toxins. PLoS One (2013) 0.78
Vitamin A supplementation modifies the association between mucosal innate and adaptive immune responses and resolution of enteric pathogen infections. Am J Clin Nutr (2011) 0.78
Clostridium difficile-related death rates in Texas 1999-2005. J Infect (2009) 0.77
United States male students who heavily consume alcohol in Mexico are at greater risk of travelers' diarrhea than their female counterparts. J Travel Med (2005) 0.77
Moderate to high use of opioid analgesics are associated with an increased risk of Clostridium difficile infection. Am J Med Sci (2012) 0.77
Development and accuracy of quantitative real-time polymerase chain reaction assays for detection and quantification of enterotoxigenic Escherichia coli (ETEC) heat labile and heat stable toxin genes in travelers' diarrhea samples. Am J Trop Med Hyg (2013) 0.77
Gender risk differences for surgical site infections among a primary coronary artery bypass graft surgery cohort: 1995-1998. Am J Infect Control (2006) 0.76
Pulsed-field gel electrophoresis for Salmonella infection surveillance, Texas, USA, 2007. Emerg Infect Dis (2010) 0.75
Pilot study of whole-blood gamma interferon response to the Vibrio cholerae toxin B subunit and resistance to enterotoxigenic Escherichia coli-associated diarrhea. Clin Vaccine Immunol (2010) 0.75
Relearning the importance of disease prevention among international travelers. Am J Gastroenterol (2007) 0.75
Coliform and Escherichia coli contamination of desserts served in public restaurants from Guadalajara, Mexico, and Houston, Texas. Am J Trop Med Hyg (2009) 0.75
Clostridium difficile: an emerging pathogen in children. Discov Med (2012) 0.75
Development and Validation of a Clostridium difficile Health-related Quality-of-Life Questionnaire. J Clin Gastroenterol (2016) 0.75
Campylobacter jejuni is not an important pathogen as a cause of diarrhea in US travelers to Mexico. J Travel Med (2010) 0.75
Travelers' diarrhea: modern concepts and new developments. Curr Treat Options Gastroenterol (2006) 0.75
Unraveling the role of host endocytic proteins in pedestal formation during enteropathogenic Escherichia coli infection. J Infect Dis (2011) 0.75
Travel health information at commercial travel websites. J Travel Med (2003) 0.75